Repligen Corporation Q2 2025 Financial Results

Repligen Corporation announced its financial results for the second quarter of 2025, reporting a revenue of $182 million, which represents a 15% year-over-year increase. The company highlighted a 17% organic non-COVID growth, driven by strong performance across all franchises, including consumables and capital equipment. Orders grew sequentially and over 20% year-over-year, marking the eighth consecutive quarter of orders exceeding non-COVID revenue. Repligen also raised its full-year revenue guidance to a range of $715 to $735 million, reflecting 12.5% to 15.5% year-over-year non-COVID organic growth. The company's GAAP net income for the quarter was $15 million, compared to $6 million in the same period last year. Adjusted net income stood at $21 million, with adjusted earnings per share of $0.37. Repligen's financial performance was supported by broad-based revenue strength, new product launches, and continued momentum in biopharma demand.